A half-point nudge to HK$21 is doing a lot of work in JPMorgan's latest note on China Merchants Securities. The bank kept its Overweight rating and lifted the H-share target from HK$20.5, betting that roughly RMB 27 billion of unrealized gains on ChangXin Memory Technologies will begin converting into reported profit from the third quarter.
The bank's analysts framed the pre-earnings window as the entry point. "China Merchants Securities is one of the few Chinese brokerages with a clear company-level earnings catalyst," JPMorgan said in the Sept. 22 research note, adding that the stock "still offers an attractive entry opportunity before third-quarter earnings catalysts emerge."
The stake is the largest CXMT exposure held by any Chinese brokerage. China Merchants Securities owns 505 million CXMT shares, or 0.74% of the memory chipmaker's issued stock, which JPMorgan values at about RMB 27 billion of unrealized gains — equivalent to roughly 2.2 times the broker's 2025 net profit. CXMT listed on the Shanghai Stock Exchange on July 27, 2026, and shareholders will begin recognizing a portion of investment gains in their third-quarter statements.
JPMorgan estimates that recognition will lift China Merchants Securities' third-quarter profit by about 190% year on year, well ahead of peers. The bank said only part of the CXMT value is currently reflected in the share price, and that the stock's outperformance versus the sector has narrowed from its July peak.
Two constraints cap how much of that gain reaches the bottom line. The CXMT holding remains inside a lock-up period, and JPMorgan said the position must be carried at a liquidity discount, meaning the full RMB 27 billion cannot be booked at once. The recognition schedule across quarters is not yet disclosed.
The call lands against a weak backdrop for the sector. Chinese brokers broadly faced headwinds in the third quarter from weakening trading activity and slowing margin-financing trends, a drag that applies to peers including CITIC Securities and Huatai Securities as much as to China Merchants Securities. That divergence is the core of JPMorgan's argument: sector beta is deteriorating while one name carries an idiosyncratic earnings event.
For holders, the setup means the third-quarter report — not the July listing — is the moment the CXMT stake converts from a balance-sheet footnote into reported earnings, and the size of the recognized slice will determine whether the 190% growth estimate holds. Investors will also watch whether the liquidity discount narrows as the lock-up rolls off, and whether other brokers with pre-IPO CXMT positions, including CITIC Securities, disclose comparable gains in the same reporting season.
This article is for informational purposes only and does not constitute investment advice.
